Preclinical Kidney Disease R&D Solutions

Online Inquiry

First Name *

Last Name *

Business Email *

Phone

Company/Institution

Job Title

Services of Interest *

When do you expect your project to start?

Project Description

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Hypertensive Nephropathy Models

Inquiry

Ace Therapeutics provides tailored preclinical research services to support drug discovery and mechanistic studies in hypertensive nephropathy. Leveraging validated disease models and advanced analytical platforms, we deliver actionable insights into renal pathophysiology, therapeutic target validation, and compound efficacy.

Why Hypertensive Nephropathy Models Matter

Hypertensive nephropathy, a leading cause of chronic kidney disease (CKD), arises from prolonged hypertension-driven renal damage. Effective preclinical modeling must replicate human disease hallmarks, including glomerulosclerosis, interstitial fibrosis, and microvascular dysfunction. Hypertensive nephropathy models enable:

Target Validation for antihypertensive and antifibrotic therapies
Biomarker Discovery to monitor disease progression
Mechanistic Insights into hypertension-renal injury pathways

Integrated Preclinical Services

Our hypertensive nephropathy platforms integrate advanced capabilities to support end-to-end research:

Customized Study Design

Protocol optimization for age, diet, or genetic background
Comorbidity integration (e.g., obesity, diabetes)

Multimodal Assessments

Transdermal GFR, urinary proteinomics
Single-cell RNA sequencing, miRNA panels
High-resolution ultrasound, contrast-enhanced MRI

Data Delivery

Raw datasets with statistical analysis
Interactive dashboards for longitudinal parameter tracking

Hypertensive Nephropathy Model Servicesf

Ace Therapeutics delivers end-to-end support across all stages of hypertensive nephropathy modeling

Model selection and customization tailored to your project goals
Protocol development including dosing regimen, uninephrectomy and induction parameters
Surgical and osmotic minipump implantation performed under strict welfare guidelines
Longitudinal blood pressure monitoring via radiotelemetry or tail-cuff plethysmography
Renal function assessments such as serum creatinine, BUN, transdermal GFR and urine protein measurement
Biomarker analysis including urinary NGAL, KIM-1, cystatin C and cytokine panels
In vivo imaging modalities (ultrasound, MRI) for structural and perfusion evaluation
Histopathology and digital pathology workflows covering H&E, Masson's trichrome, collagen I/III and α-SMA immunostaining

Model	Induction Method	Key Endpoints
DOCA-salt	Uninephrectomy plus DOCA pellet with 1% NaCl drinking water	BP rise, proteinuria, macrophage infiltration, collagen deposition
Angiotensin II infusion	Osmotic minipump delivering 0.7–1.4 mg/kg/day Ang II	Gradual BP elevation, renal inflammation, fibrosis
Dahl salt-sensitive rat	High-salt diet (4–8%)	Salt-sensitive hypertension, GFR decline, proteinuria
Spontaneously hypertensive rat (SHR)	Genetic predisposition	Progressive BP rise, nephrosclerosis
Goldblatt two-kidney one-clip (2K1C)	Renal artery clipping	Renin-dependent hypertension, glomerular injury

Model Validation and Quality Assurance

Reproducibility and translational relevance are ensured through:

Baseline profiling of physiological and biochemical markers
Multicohort reproducibility checks across independent studies
Histological grading of glomerulosclerosis, interstitial fibrosis and tubular atrophy
Quantitative image analysis for fibrosis and inflammatory cell infiltration
Standard operating procedures aligned to institutional welfare standards

Applications in Drug Development

These models support:

Lead candidate screening and prioritization
Mechanism of action studies for antihypertensive and antifibrotic agents
Biomarker identification for patient stratification
Safety profiling of novel compounds in hypertensive settings

Why Choose Us?

Proven expertise in renal pathophysiology and model implementation
Flexible customization to replicate comorbidities (e.g., diabetes, obesity)
End-to-end project management with dedicated scientific advisors
Integrated data packages with regulatory-grade documentation
Commitment to animal welfare and reproducibility

Frequently Asked Questions (FAQs) About Hypertensive Nephropathy Models

How do I choose between DOCA-salt and Dahl models for salt-sensitive hypertension studies?

DOCA-salt models suit short-term sodium overload studies, while Dahl rats better mimic chronic, diet-driven nephropathy.

Can you incorporate diabetic conditions into hypertensive nephropathy models?

Yes. We combine high-fat diets or streptozotocin-induced diabetes with hypertension protocols.

What endpoints are measured in Angiotensin II infusion studies?

Standard metrics include blood pressure, renal fibrosis (picrosirius red), and oxidative stress markers (8-OHdG, NOX4).

Do you offer pharmacokinetic (PK) analysis alongside efficacy studies?

Yes. Integrated PK/PD assessments are available to evaluate renal drug distribution.

How is model reproducibility ensured?

A: Each model undergoes baseline physiological profiling and inter-laboratory validation checks.